Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)

Anouk K. M. Claessens, Monique E. M. M. Bos, Marta Lopez-Yurda, Jeanette M. Bouma, Jeany M. Rademaker-Lakhai, Aafke H. Honkoop, Hiltje de Graaf, Edith van Druten, Laurence J. C. van Warmerdam, Maurice J. C. van der Sangen, Vivianne C. G. Tjan-Heijnen, Frans L. G. Erdkamp, Dutch Breast Canc Res Grp BOOG

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)413-423
Number of pages11
JournalBreast Cancer Research and Treatment
Volume172
Issue number2
DOIs
Publication statusPublished - 1 Nov 2018

Keywords

  • Metastatic breast cancer
  • Chemotherapy
  • Scheduling
  • Duration
  • Paclitaxel
  • Bevacizumab
  • BEVACIZUMAB PLUS PACLITAXEL
  • PHASE-III TRIAL
  • LOCALLY RECURRENT
  • OPEN-LABEL
  • DOUBLE-BLIND
  • CHEMOTHERAPY
  • THERAPY
  • CAPECITABINE
  • SURVIVAL
  • EFFICACY

Cite this

Claessens, A. K. M., Bos, M. E. M. M., Lopez-Yurda, M., Bouma, J. M., Rademaker-Lakhai, J. M., Honkoop, A. H., de Graaf, H., van Druten, E., van Warmerdam, L. J. C., van der Sangen, M. J. C., Tjan-Heijnen, V. C. G., Erdkamp, F. L. G., & Dutch Breast Canc Res Grp BOOG (2018). Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Research and Treatment, 172(2), 413-423. https://doi.org/10.1007/s10549-018-4906-8